BioNTech and Bristol Myers Squibb unveiled promising Phase 2 data for pumitamig (BNT327), a bispecific antibody targeting PD-1 and VEGF, in extensive-stage small cell lung cancer (ES-SCLC). The trial reported tumor shrinkage in 76% of participants and 100% disease control, advancing expectations for the ongoing Phase 3 study combining pumitamig with chemotherapy. This compound represents a competitive entry in the bispecific antibody cancer immunotherapy space focused on immune checkpoint and angiogenesis pathways.